Botulinum Toxin: State of the Art

被引：142
作者：
Jankovic, Joseph [1 ,2 ]
机构：
[1] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA
来源：
MOVEMENT DISORDERS | 2017年 / 32卷 / 08期
关键词：
botulinum toxin; dystonia; blepharospasm; hemifacial spasm; spasticity; tremor; tics; TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; CRANIAL-CERVICAL DYSTONIA; NEUROTOXIN TYPE-A; FLU-LIKE SYMPTOMS; AMERICAN-ACADEMY; DOUBLE-BLIND; SPASTICITY; EFFICACY; THERAPEUTICS; IMMUNOGENICITY;
D O I：
10.1002/mds.27072
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions. In addition to onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and RimabotulinumtoxinB (Myobloc or NeuroBloc) there are other novel botulinun neurotoxin products currently in development. With a better understanding of the cellular mechanisms of botulinun neurotoxin and advances in biotechnology, future botulinun neurotoxin products will likely be even more effective and customized to the specific indication and tailored to the needs of the patients. (C) 2017 International Parkinson and Movement Disorder Society
引用
收藏
页码：1131 / 1138
页数：8
相关论文
共 77 条
[1]   Botulinum toxin as a biological weapon - Medical and public health management [J].
Arnon, SS ;
Schechter, R ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Hauer, J ;
Layton, M ;
Lillibridge, S ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Swerdlow, DL ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08) :1059-1070
[2]   Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule [J].
Atassi, M. Zouhair ;
Jankovic, Joseph ;
Steward, Lance E. ;
Aoki, K. Roger ;
Dolimbek, Behzod Z. .
IMMUNOBIOLOGY, 2012, 217 (01) :17-27
[3]   Flu-like symptoms following botulinum toxin therapy [J].
Baizabal-Carvallo, Jose F. ;
Jankovic, Joseph ;
Pappert, Eric .
TOXICON, 2011, 58 (01) :1-7
[4]   Flu-like Symptoms and Associated Immunological Response Following Therapy with Botulinum Toxins [J].
Baizabal-Carvallo, Jose Fidel ;
Jankovic, Joseph ;
Feld, Jordan .
NEUROTOXICITY RESEARCH, 2013, 24 (02) :298-306
[5]   Treatment of camptocormia with botulinum toxin [J].
Bertram, Kelly L. ;
Stirpe, Paola ;
Colosimo, Carlo .
TOXICON, 2015, 107 :148-153
[6]  
BRIN MF, 2002, SCI THERAPEUTIC ASPE, P1
[7]   Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay [J].
Brin, Mitchell F. ;
Comella, Cynthia L. ;
Jankovic, Joseph ;
Lai, Francis ;
Naumann, Markus .
MOVEMENT DISORDERS, 2008, 23 (10) :1353-1360
[8]   All Roads Lead to Neuroscience: The 2013 Nobel Prize in Physiology or Medicine [J].
Brose, Nils .
NEURON, 2014, 81 (04) :723-727
[9]   Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism [J].
Bruno, Veronica A. ;
Fox, Susan H. ;
Mancini, Deborah ;
Miyasaki, Janis M. .
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2016, 43 (05) :697-702
[10]   BOTULINUM NEUROTOXIN TYPE A-CLEAVED SNAP25 IS CONFINED TO PRIMARY MOTOR NEURONS AND LOCALIZED ON THE PLASMA MEMBRANE FOLLOWING INTRAMUSCULAR TOXIN INJECTION [J].
Cai, Brian B. ;
Francis, Joseph ;
Brin, Mitchell F. ;
Broide, Ron S. .
NEUROSCIENCE, 2017, 352 :155-169
12345678